Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO33%
Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Jiangsu Alphamab Biopharmaceuticals Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| JSKN003 NCT06079983 |
P3 | Recruiting | Breast Cancer | 400 | 2026-04-01 (+12 mo) |
| JSKN003 NCT05744427 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 725 | 2026-07-30 (+19 mo) |
| JSKN003 NCT06751485 |
P3 | Not yet recruiting | Ovarian Cancer; Primary Peritoneal | 430 | 2026-12-30 |
| JSKN033 NCT06770881 |
P1/2 | Not yet recruiting | Advanced Malignant Tumors | 430 | 2026-12-31 |
| JSKN016 NCT06942234 |
P1/2 | Recruiting | Inoperable Locally Advanced HER2-Negative Breast Cancer; Metastatic HER2-Negative Breast Cancer | 180 | 2027-06-30 |
| JSKN016 NCT06775483 |
P2 | Not yet recruiting | Advanced Non-small Cell Lung Cancer | 220 | 2027-06-30 |
| JSKN033 Injection NCT07283198 |
P2 | Not yet recruiting | Non Small Cell Lung Cancer (NSCLC) | 160 | 2027-08-30 |
| JSKN033 NCT07497074 |
P2 | Not yet recruiting | Cervical Cancer | 78 | 2027-10 |
| JSKN016 Q2W NCT07336771 |
P1/2 | Not yet recruiting | Metastatic Breast Cancer; Locally Advanced Breast Cancer (LABC) | 60 | 2027-12 |
| JSKN033 NCT07797153 |
P3 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 368 | 2028-12 |
| JSKN016 Injection NCT07533123 |
P3 | Recruiting | Triple Negative Breast Cancer | 364 | 2029-03-17 |